[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
대학원 진학 설문조사
스폰서배너광고 안내  배너1 배너2
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
홍연희 (Yeonhee Hong)
조회 88  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
열기 Authors and Affiliations


Skeletal muscle atrophy is defined as a reduction of muscle mass caused by excessive protein degradation. However, the development of therapeutic interventions is still in an early stage. Although glucagon‐like peptide‐1 receptor (GLP‐1R) agonists, such as exendin‐4 (Ex‐4) and dulaglutide, are widely used for the treatment of diabetes, their effects on muscle pathology are unknown. In this study, we investigated the therapeutic potential of GLP‐1R agonist for muscle wasting and the mechanisms involved.

Mouse C2C12 myotubes were used to evaluate the in vitro effects of Ex‐4 in the presence or absence of dexamethasone (Dex) on the regulation of the expression of muscle atrophic factors and the underlying mechanisms using various pharmacological inhibitors. In addition, we investigated the in vivo therapeutic effect of Ex‐4 in a Dex‐induced mouse muscle atrophy model (20 mg/kg/day i.p.) followed by injection of Ex‐4 (100 ng/day i.p.) for 12 days and chronic kidney disease (CKD)‐induced muscle atrophy model. Furthermore, we evaluated the effect of a long‐acting GLP‐1R agonist by treatment of dulaglutide (1 mg/kg/week s.c.) for 3 weeks, in DBA/2J‐mdx mice, a Duchenne muscular dystrophy model.

Ex‐4 suppressed the expression of myostatin (MSTN) and muscle atrophic factors such as F‐box only protein 32 (atrogin‐1) and muscle RING‐finger protein‐1 (MuRF‐1) in Dex‐treated C2C12 myotubes. The suppression effect was via protein kinase A and protein kinase B signalling pathways through GLP‐1R. In addition, Ex‐4 treatment inhibited glucocorticoid receptor (GR) translocation by up‐regulating the proteins of GR inhibitory complexes. In a Dex‐induced muscle atrophy model, Ex‐4 ameliorated muscle atrophy by suppressing muscle atrophic factors and enhancing myogenic factors (MyoG and MyoD), leading to increased muscle mass and function. In the CKD muscle atrophy model, Ex‐4 also increased muscle mass, myofiber size, and muscle function. In addition, treatment with a long‐acting GLP‐1R agonist, dulaglutide, recovered muscle mass and function in DBA/2J‐mdx mice.

GLP‐1R agonists ameliorate muscle wasting by suppressing MSTN and muscle atrophic factors and enhancing myogenic factors through GLP‐1R‐mediated signalling pathways. These novel findings suggest that activating GLP‐1R signalling may be useful for the treatment of atrophy‐related muscular diseases.

Keywords : Skeletal muscle atrophy, GLP‐1R agonists, Dexamethasone, Glucocorticoid receptor, Chronic kidney disease, Duchenne muscular dystrophy

- 형식: Research article
- 게재일: 2019년 04월 (BRIC 등록일 2019-04-26)
- 연구진: 국내연구진태극기
  댓글 0
Springer Nature
홍연희 님 전체논문보기 >
전희숙 (가천대학교 약학과)
Google (by Yeonhee Hong)
Pubmed (by Yeonhee Hong)
프리미엄 Bio일정 Bio일정 프리미엄 안내
의료기기 GMP의 이해과정(재직자 과정)
의료기기 GMP의 이해과정(재직자 과정)
날짜: 2019.06.18~20
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실2
제6회 KXA(대한 이종이식 연구회) 심포지엄
제6회 KXA(대한 이종이식 연구회) 심포지엄
날짜: 2019.05.30
장소: 서울대학교 의과대학 삼성암연구동 2층 이건희홀
비임상시험 계획서 및 보고서 Review 과정(재직자 과정)
비임상시험 계획서 및 보고서 Review 과정(재직자 과정)
날짜: 2019.05.29~31
장소: 경기도 성남시 분당구 판교로289번길 20 스타트업캠퍼스 2층 세미나실1
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS